Navigation Links
New treatment gives hope for pulmonary fibrosis patients
Date:5/20/2008

ATS 2008, TORONTOPatients with idiopathic pulmonary fibrosis (IPF) may have a new treatment option, according to researchers in Japan.

In a Phase III, double-blind, placebo-controlled clinical trial, the investigators discovered that a daily dose of pirfenidone could slow the progression of IPF, reducing the loss of lung capacity. The results will be announced at the American Thoracic Societys 2008 International Conference in Toronto on Tuesday, May 20.

The most common treatment for IPF is anti-inflammatory agents such as steroids, said lead researcher Takashi Ogura, M.D., of Kanagawa Cardiovascular and Respiratory Center in Yokohama, Japan. However our study confirmed that pirfenidone, the main action of which is thought to be antifibrotic, achieved a therapeutic effect on IPF. I expect that our study will serve as a guide to develop a new therapy for IPF in the future.

The researchers recruited a total of 275 Japanese patients with mild to moderate IPF and randomized them to a high dose pirfenidone (1,800 mg/day) group, a low dose pirfenidone group (1,200 mg/day) and a placebo group. They measured lung capacity (vital capacity or VC) and progression-free survival, defined as a period without death or a greater than 10 percent decrease in VC, to determine the effectiveness of the regimens.

At the end of one year, they found that patients who had been randomized to the high dose regimen had significantly lower loss of VC than the placebo group. Furthermore, pirfenidone slowed the overall deterioration of IPF compared to the placebo.

Taken altogether, our study demonstrated positive clinical effects of pirfenidone that suppresses the progress of IPF and potentially contributes to improving the outcomes of patients with IPF, said Dr. Ogura.

Pirfenidone represents new hope, not only for IPF patients who currently have no curative treatment options, but because it is thought to be an antifibrotic agent, it may be able to treat other fibrotic lung diseases, such as interstitial pneumonia with collagen vascular disease and extrapulmonary fibrosis.

We will continue the follow-up of the patient cohort included in this study to identify whether pirfenidone can contribute to prolonged survival in patients with IPF, said Dr. Ogura. Other clinical studies of pirfenidone are also being conducted in the U.S. and Europe, and we hope that our results will be replicated there.


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Mission Pharmacal Launches Ferralet(R) 90 for Treatment of the Leading Cause of Anemia in the U.S.
2. Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa
3. Mapping of prostate cancer genes opens the door to new treatments
4. Many Diabetics Dont Get Necessary Blood Pressure Treatment
5. MR imaging accurately determines prostate cancer treatment failure
6. Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment
7. Old antibiotic may find new life as a stroke treatment
8. Radiofrequency ablation is effective treatment for dysplasia in Barretts esophagus
9. New Hair Loss Treatment Proves Effectiveness
10. Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome
11. Advances Aid Treatment, Diagnosis of Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Minn. (PRWEB) , ... March 29, 2017 , ... ... medical office buildings (MOBs) and other outpatient facilities, and who are the most ... exclusively at those questions, Revista and Healthcare Real Estate Insights (HREI) found that ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a premium medical cannabis ... the company’s executive management team with prominent executives from both inside and outside the ... Operating Officer, Ted Dumbauld , who has more than twenty years of business ...
(Date:3/29/2017)... ... 29, 2017 , ... HealthCareMandA.com will host an important webinar — Home Health ... ET. A recording of the webinar will also be made available following its live ... hospice companies are still popular targets for healthcare investors. This highly fragmented sector bounced ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of the most ... touted to be the next revolution in our fight against this complex disease. One ... of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few ...
(Date:3/29/2017)... , ... March 29, 2017 ... ... and South Hills of Pittsburgh now have easier access to the robotic-assisted ... by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , Mar 29, 2017  Providence Medical Technology, ... the addition of two industry veterans to the ... joined the company to lead Global Marketing, and ... Together, Mr. Lynch and Mr. Scott have over ... Mr. Lynch joins the company with over ...
(Date:3/29/2017)... March 29, 2017  Glenmark Pharmaceuticals, a global ... 301, an investigational fixed-dose combination of mometasone furoate ... twice-daily as a nasal spray being studied for ... are from a recently completed Phase 3 trial ... combination therapy versus mometasone, olopatadine or placebo. ...
(Date:3/29/2017)... , March 29, 2017  The Pharmaceutical Care ... a new PhRMA report on patient out-of-pocket spending: ... Medicare and Medicaid Services (CMS), the average amount spent ... 13% of drug spending in 2016, down from 23% ... a pricing problem, not a coverage problem. Health plans ...
Breaking Medicine Technology: